Plain English Summary
Background and study aims
Adults with learning disabilities are as likely to have depression as adults who do not have
learning disabilities. However, not much is known about what treatments help adults with
learning disabilities and depression. Behavioural activation is a psychological therapy for depression that has been shown to work as well as other psychological treatments like cognitive behavioural therapy. The advantage of behavioural activation for adults with learning disabilities is that people do not need to have good verbal communication skills. Behavioural activation gets people with depression
involved in positive activities. This includes everyday activities which they may have stopped doing because of their low mood. The proposed study would investigate whether a behavioural activation treatment
adapted for adults with learning disabilities and depression works.
Who can participate?
The study aims to recruit 166 men and women with mild learning disabilities and depression. All the participants will be 18 years of age and above.
What does the study involve?
Over a period of two years, study participants will be invited to take part in behavioural activation treatment for depression or supported self-help treatment. The treatment that the participant gets will be decided by a process called randomisation, which is like the toss of a coin. The treatments last for between 8 - 12 weeks. At the end of the study we will compare the mood and sense of well-being of participants who had received the behavioural activation treatment with those given guided self-help.
What are the possible risks and benefits of participating?
The possible benefit to participants is that their level of distress will reduce. They may also take part in more purposeful activity, enjoy better relationships with others, and have more opportunity for social inclusion. There are no anticipated major risks from taking part in the study, based on the findings from pilot work trying out the interventions. However, those taking part in the study are depressed and their condition will sometimes become worse. Therefore, a close watch will be kept in case taking part in the study has caused any harm
Where is the study run from?
The study has been set up by the Universities of Glasgow, Bangor and Lancaster.
When is the study starting and how long is it expected to run for?
It is anticipated that recruitment will start in mid-2013 in Scotland. If recruitment is successful in the first year then recruitment will also start England and Wales in 2014. Participants will be enrolled in the study for a year, so that they can be followed-up after their treatment has finished.
Who is funding the study?
Funding has been provided by NIHR Health Technology Assessment Programme.
Who is the main contact?
Professor Andrew Jahoda
Andrew.Jahoda@glasgow.c.uk
Trial website
Contact information
Type
Scientific
Primary contact
Prof Andrew Jahoda
ORCID ID
Contact details
Institute of Health and Wellbeing
University of Glasgow
Academic Centre
Gartnavel Royal Hospital
1055 Great Western Road
Glasgow
G12 0XH
United Kingdom
+44(0)141 211 0282
Andrew.Jahoda@glasgow.ac.uk
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
HTA 10/104/34
Study information
Scientific title
A randomised controlled trial comparing a behavioural activation treatment for depression in adults with learning disabilities with an attention control
Acronym
Study hypothesis
To assess the clinical (reduction in depressive symptoms) and cost effectiveness of a behavioural activation intervention for adults with learning disabilities.
Secondary objectives:
Evaluate whether behavioural activation, compared to an attention control intervention leads to:
1. A greater reduction in anxiety symptoms
2. Higher levels of activity
3. Greater improvement in quality of life
4. Improved carers' sense of self-efficacy in supporting depressed adults
5. improved carers' relationships with the depressed adults
More details can be found at http://www.nets.nihr.ac.uk/projects/hta/1010434
Protocol can be found at http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0004/81724/PRO-10-104-34.pdf
Ethics approval
Not provided at time of registration
Study design
Multi-centre single-blind randomized controlled design
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Other
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Depression
Intervention
Behavioural Activation: The treatment is designed to be delivered to individuals alongside a carer who provides regular support to them. It is a structured, time limited, manualised psychological therapy, developed to treat those with a learning disability and depressive symptoms.
The treatment is divided into two phases, starting with an assessment period (4 sessions), where the patient with learning disabilities and their carer are socialised into the model and an individual formulation is developed. The subsequent 5-10 active treatment sessions focus on: (i) Recovering lost skills and interests, and new skills training, (ii) Graded exposure to reduce avoidant behaviours, and (iii) Targeting inherently reinforcing activity, and activity likely to increase access to other positive reinforcers. The final two sessions (11-12) after the active treatment phase have a future focus, and are concerned with helping the patient and carer to maintain and build on progress they have made.
Guided self-help: The self-help resources were designed to be used by patients with learning disabilities along with the support of a carer. There will be an initial meeting, with the patient and carer to explain the materials and provide coaching in their use, then 8 sessions to support the dyads in their use of the self-help materials. Although the materials were designed to be accessible, carer support is essential for their delivery as the patients themselves are expected to have few, if any, literacy skills. The focus is psycho-educational and the first two sessions with the patient begin by looking at the nature of depression, before going on to outline how depressive symptoms can be tackled. The materials focus on key topics including feeling down, sleep, exercise, and problem solving.
The treatment duration for both arms of the trial is approximately 4 months, with a 12 month follow-up period following randomisation.
Intervention type
Behavioural
Phase
Drug names
Primary outcome measures
Self-report of depressive symptoms, using the Glasgow Depression Scale, an instrument validated for use with adults who have Learning Disabilities. Data will be at collected at baseline, 4 months post randomisation and 12 months post randomisation.
Secondary outcome measures
1. Self-reports of anxiety
2. Carer proxy reports of depression, and
3. Activity/engagement in community life.
4. An economic analysis will compare the costs of the treatment with the quality of life benefits as measured by the EQ-5D.
Data will be at collected at baseline, 4 months post randomisation and 12 months post randomisation.
Overall trial start date
01/01/2013
Overall trial end date
30/09/2016
Reason abandoned
Eligibility
Participant inclusion criteria
1. A learning disability
2. Over 18 years old
3. Clinically significant depression
4. Is able to give informed consent to participate
5. A level of expressive and receptive communication skill in English (reading skills not required) to allow participation in the treatment
6. Has a family member or paid carer who has supported them for a minimum of six months, is available for weekly-fortnightly treatment sessions with the practitioner, and who currently provides a minimum of 2 hours support per week to the patient.
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
166
Participant exclusion criteria
1. Suicidal
2. A measured IQ of >75
3. Factors that prevent the patient from interacting with the carer and therapist or retaining information from the therapy (e.g. dementia, significant agitation, withdrawal arising from psychosis), and/or
4. Does not consent to her/his GP being contacted about their participation in the study
Recruitment start date
01/07/2013
Recruitment end date
30/09/2016
Locations
Countries of recruitment
United Kingdom
Trial participating centre
University of Glasgow
Glasgow
G12 0XH
United Kingdom
Sponsor information
Organisation
NIHR Health Technology Assessment Programme (UK)
Sponsor details
Alpha House
University of Southampton Science Park
Southampton
SO16 7NS
United Kingdom
+44(0)23 8059 5586
hta@hta.ac.uk
Sponsor type
Government
Website
Funders
Funder type
Government
Funder name
NIHR Health Technology Assessment Programme - HTA (UK) 10/104/34
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary
2015 protocol in: http://www.ncbi.nlm.nih.gov/pubmed/26714891